Eli Lilly Surges On Strong Earnings As Mounjaro And Zepbound Sales Soar

📆 04/02/46 02:31 م
📰 ForbesTech

⏱ Reading Time:
9 sec. here
11 min. at publisher
📊 Quality Score:
News: 38%
Publisher: 59%

Eli Lilly أخبار

Novo Nordisk,Tirzepatide,Zepbound

Robert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.

Pharma titan Eli Lilly on Thursday reported strong demand for its weight loss and diabetes drugs Zepbound and Mounjaro, smashing analysts’ expectations in the face ofEli Lilly reported $11.3 billion in revenue and $2.97 billion in net profit for the second quarter of 2024.

Lilly reported $3.28 earnings per share, besting expectations of $2.74, and raised the range of its annual forecast $2.05 to earnings per share between $15.10 to $15.60.

اكتب تعليق

لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر:

المملكة العربية السعودية أحدث الأخبار, المملكة العربية السعودية عناوين